+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-1 Receptor Antagonist Market - Global Forecast 2025-2030- Product Image
IL-1 Receptor Antagonist Market - Global Forecast 2025-2030- Product Image
Sale

IL-1 Receptor Antagonist Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6135097
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The IL-1 receptor antagonist market is positioned for substantial evolution as it advances into broader therapeutic indications and leverages both technological and regulatory innovation. Senior decision-makers will find that this market is defined not only by emerging clinical efficacy, but also by rapid adaptation to supply chain disruptions, new reimbursement models, and the push toward patient-centric care strategies.

Market Snapshot: IL-1 Receptor Antagonist Market Overview

The global market for IL-1 receptor antagonists features dynamic growth driven by expanding indications across autoinflammatory diseases, increasing adoption of biologic therapies, and enhanced patient-centric care models. With a rising pipeline of next-generation candidates and accelerated regulatory approvals for novel inflammatory disorder applications, this therapy class is set to transition from orphan disease solutions to a mainstream component of immune-mediated disease management. Key growth is supported by advanced delivery systems, evolving digital health solutions, and mature biosimilar pathways, all operating under the impact of new tariff measures and regional reimbursement shifts.

Scope & Segmentation: Comprehensive Market Coverage

This report delivers in-depth analysis by focusing on critical market segments, leading technologies, and key geographies. Market segmentation includes:

  • Therapeutic Indications: Cryopyrin-Associated Periodic Syndromes (Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease), Gout (Acute and Chronic), Rheumatoid Arthritis (Adult, Juvenile).
  • Routes of Administration: Intraperitoneal, Intravenous (infusion bag, vial), Subcutaneous (pre-filled pen, prefilled syringe in multi-dose and single-dose formats).
  • Dosage Forms: Auto-injectors, liquid formulations, lyophilized powder, prefilled syringes (multi-dose and single-dose).
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies, specialty pharmacy networks.
  • End-Use Settings: Home healthcare, hospital, and specialty clinic environments.
  • Patient Categories: Adult and pediatric cohorts.
  • Regional Markets: Americas (USA: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., AstraZeneca PLC, Johnson & Johnson, GlaxoSmithKline plc.

SEO Focus: IL-1 Receptor Antagonist Market Insights

This report ensures high visibility for stakeholders tracing developments in IL-1 receptor antagonist innovation, diversification, and commercial strategy, while also maintaining clarity about competitive positioning and growth levers.

Key Takeaways for Decision-Makers

  • Expansion into mainstream indications—such as gout and rheumatoid arthritis—marks a shift from niche to widely adopted treatment protocols for IL-1 receptor antagonists.
  • Advances in manufacturing, including continuous bioprocessing and stability-enhancing technologies, facilitate scalable production and open doors to novel delivery formats like auto-injectors and ready-to-use pens.
  • Digital health interventions, particularly wearable monitoring and mobile dosing platforms, are significantly improving adherence support and real-world outcome measurement, leading to enhanced patient engagement.
  • The competitive landscape is shaped by both established innovator portfolios and the emergence of agile, biosimilar-focused entrants relying on collaborative R&D and licensing strategies.
  • Strategic partnerships across the value chain—including contract manufacturing and technology providers—are driving cost efficiencies and enabling integrated service offerings for market participants.

Tariff Impact on Supply Chain and Economics

The enhanced United States tariff measures introduced in 2025 have increased costs for APIs and raw materials, prompting manufacturers to shift toward domestic sourcing and vertically integrated production. These changes have led to renegotiated supply contracts and adoption of inventory optimization strategies. In response, companies are also pursuing alternative suppliers and process intensification to sustain commercial viability while recalibrating pricing strategies to balance payer, provider, and patient needs.

Methodology & Data Sources

The analysis applies a mixed-method paradigm, utilizing peer-reviewed literature, regulatory filings, trial registries, and proprietary data for robust secondary validation. Structured interviews were conducted with industry leaders, R&D executives, manufacturing and supply specialists, and reimbursement experts. This approach provided triangulated insights across clinical, regulatory, supply chain, and payer landscapes to ensure data reliability and actionable guidance.

Why This Report Matters for Executives

  • Enable informed investment in future-ready IL-1 receptor antagonist formulations and commercialization strategies aligned with emerging market dynamics.
  • Identify critical opportunities to strengthen supply resilience, engage with new digital health models, and refine market access approaches under changing tariff landscapes.
  • Leverage comprehensive segmentation analysis to tailor portfolio development and strategic partnerships for optimal market positioning.

Conclusion

IL-1 receptor antagonists are poised to transform autoinflammatory disease management by integrating advanced science, regional insight, and adaptable commercial strategies. Stakeholders prepared to align with these trends will realize sustainable growth and improved patient outcomes in a rapidly evolving landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of the biologic pipeline with novel IL-1 receptor antagonists targeting rare autoinflammatory diseases
5.2. Rising adoption of subcutaneous self-administered IL-1 receptor antagonists in outpatient care settings
5.3. Competitive pressures from emerging biosimilars challenging established IL-1 receptor antagonist brands in key markets
5.4. Integration of IL-1 receptor antagonists into combination therapy regimens for cardiovascular risk reduction in high-risk patients
5.5. Development of long-acting IL-1 receptor antagonist formulations aimed at improving patient adherence and dosing convenience
5.6. Real-world evidence studies highlighting the efficacy of IL-1 receptor antagonists in managing COVID-19 induced cytokine storm patients
5.7. Advances in precision medicine using genetic and biomarker profiling to optimize IL-1 receptor antagonist treatment in rheumatic diseases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. IL-1 Receptor Antagonist Market, by Indication
8.1. Introduction
8.2. Cryopyrin-Associated Periodic Syndromes
8.2.1. Familial Cold Autoinflammatory Syndrome
8.2.2. Muckle-Wells Syndrome
8.2.3. Neonatal-Onset Multisystem Inflammatory Disease
8.3. Gout
8.3.1. Acute Gout
8.3.2. Chronic Gout
8.4. Rheumatoid Arthritis
8.4.1. Adult Rheumatoid Arthritis
8.4.2. Juvenile Rheumatoid Arthritis
9. IL-1 Receptor Antagonist Market, by Route Of Administration
9.1. Introduction
9.2. Intraperitoneal
9.3. Intravenous
9.3.1. Infusion Bag
9.3.2. Vial
9.4. Subcutaneous
9.4.1. Pre-Filled Pen
9.4.2. Prefilled Syringe
9.4.2.1. Multi-Dose
9.4.2.2. Single-Dose
10. IL-1 Receptor Antagonist Market, by Dosage Form
10.1. Introduction
10.2. Auto-Injector
10.3. Liquid
10.4. Powder
10.5. Prefilled Syringe
10.5.1. Multi-Dose
10.5.2. Single-Dose
11. IL-1 Receptor Antagonist Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.5. Specialty Pharmacy
12. IL-1 Receptor Antagonist Market, by End-User
12.1. Introduction
12.2. Home Healthcare
12.3. Hospital
12.4. Specialty Clinic
13. IL-1 Receptor Antagonist Market, by Patient Type
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas IL-1 Receptor Antagonist Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa IL-1 Receptor Antagonist Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific IL-1 Receptor Antagonist Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Swedish Orphan Biovitrum AB
17.3.2. Regeneron Pharmaceuticals, Inc.
17.3.3. Novartis AG
17.3.4. Pfizer Inc.
17.3.5. Amgen Inc.
17.3.6. Sanofi S.A.
17.3.7. AbbVie Inc.
17.3.8. AstraZeneca PLC
17.3.9. Johnson & Johnson
17.3.10. GlaxoSmithKline plc
18. ResearchAI19. ResearchStatistics20. ResearchContacts21. ResearchArticles22. Appendix
List of Figures
FIGURE 1. IL-1 RECEPTOR ANTAGONIST MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IL-1 RECEPTOR ANTAGONIST MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IL-1 RECEPTOR ANTAGONIST MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. IL-1 RECEPTOR ANTAGONIST MARKET: RESEARCHAI
FIGURE 28. IL-1 RECEPTOR ANTAGONIST MARKET: RESEARCHSTATISTICS
FIGURE 29. IL-1 RECEPTOR ANTAGONIST MARKET: RESEARCHCONTACTS
FIGURE 30. IL-1 RECEPTOR ANTAGONIST MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IL-1 RECEPTOR ANTAGONIST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ACUTE GOUT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ACUTE GOUT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULT RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY JUVENILE RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY JUVENILE RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INFUSION BAG, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INFUSION BAG, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PRE-FILLED PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MULTI-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY MULTI-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SINGLE-DOSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 162. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 163. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 164. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 165. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 166. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 167. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 170. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 171. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 172. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 173. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 174. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 175. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 176. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 177. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 178. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 179. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 182. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 183. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 190. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 191. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY GOUT, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM IL-1 RECEPTOR ANTAGONIST MARKET SIZE, BY PREFILLED SYRINGE, 2025-2030 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this IL-1 Receptor Antagonist Market report include:
  • Swedish Orphan Biovitrum AB
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Amgen Inc.
  • Sanofi S.A.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • GlaxoSmithKline plc

Related Topics

Related Reports

IL-12 Receptor Antagonist Market - Global Forecast 2025-2030 - Product Image

IL-12 Receptor Antagonist Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
IL-6 Receptor Antagonist Market - Global Forecast 2025-2030 - Product Image

IL-6 Receptor Antagonist Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
IL-6 Receptor Antagonist - Pipeline Insight, 2025 - Product Image

IL-6 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Interleukin 8 Receptor Antagonists - Pipeline Insight, 2025 - Product Image

Interleukin 8 Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Kineret Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Kineret Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.